LearnGlossaryMarketStocksSuperinvestorsSign in

AMLX

Amylyx Pharmaceuticals, Inc.

Healthcare · $3.2B market cap

Verdict

We can't put a fair value on AMLX right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-29.2% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-33.1%✗

Follow AMLX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Firestone Karen

director · 2026-08-31

Option exercise

$126K

Firestone Karen

director · 2026-08-31

Option exercise

$44K

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works